Molecular structure and pharmacological properties of bosutinib/bosutinib

Bosutinib/Bosutinib is a key second-generation tyrosine kinase inhibitor (TKI) widely used in the treatment of Philadelphia chromosome-positive chronic myelogenous leukemia (CML). This drug has been approved by relevant regulatory agencies and is suitable for patients with CML in the chronic, accelerated and blast phases, especially those who have shown resistance or intolerance to previous treatments. The chemical structure of bosutinib is the basis of its efficacy and function and is of great significance.

The chemical name of bosutinib is3-quinolonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-piperazinyl)propoxy] -Hydrate (1:1), whose molecular formula is C26H29Cl2N5O3·H2O, shows that it exists in the monohydrate form with a molecular weight of 548.46 (for the monohydrate), while in the anhydrous state it is 530.46. The chemical structure contains multiple functional groups that play a key role in pharmacological activity.

The core structure of bosutinib is a quinoline ring, which has a direct impact on the binding ability of the drug to its targetBCR::ABL1 tyrosine kinase. In addition, the molecule contains two chlorine atoms, as well as various methoxy and amino substituents that are critical to its antitumor activity. Through this unique molecular design, bosutinib can efficiently bind to BCR::ABL1 tyrosine kinase, thereby inhibiting the function of the enzyme and preventing the growth and spread of tumor cells.

In terms of clinical use, bosutinib is supplied in different dosage forms, including tablets and capsules. The specific dosages are100 mg, 400 mg and 500 mg tablets, and 50 mg and 100 mg capsules. These dosage settings are highly flexible and can better meet the treatment needs of different patients, making bosutinib one of the important options for the treatment of CML. Through a reasonable medication regimen, doctors can develop a personalized treatment plan based on the patient's specific condition in order to achieve the best treatment effect.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d5929f91-6496-4c0e-97e8-0bd524e15763